MA52924A - Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule - Google Patents
Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de mouleInfo
- Publication number
- MA52924A MA52924A MA052924A MA52924A MA52924A MA 52924 A MA52924 A MA 52924A MA 052924 A MA052924 A MA 052924A MA 52924 A MA52924 A MA 52924A MA 52924 A MA52924 A MA 52924A
- Authority
- MA
- Morocco
- Prior art keywords
- combinations
- topical formulations
- formulations including
- adhesion proteins
- mold adhesion
- Prior art date
Links
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 1
- 229960005127 montelukast Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000012049 topical pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017091819 | 2017-07-05 | ||
| CN2018087058 | 2018-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52924A true MA52924A (fr) | 2021-04-28 |
Family
ID=64949737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052924A MA52924A (fr) | 2017-07-05 | 2018-07-04 | Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11672792B2 (https=) |
| EP (1) | EP3648767A4 (https=) |
| JP (1) | JP7288404B2 (https=) |
| KR (1) | KR102785243B1 (https=) |
| CN (3) | CN113491696A (https=) |
| AU (1) | AU2018295944B2 (https=) |
| CA (1) | CA3068818A1 (https=) |
| MA (1) | MA52924A (https=) |
| MX (1) | MX2020000029A (https=) |
| MY (1) | MY201703A (https=) |
| SG (1) | SG11201911841PA (https=) |
| TW (1) | TWI874298B (https=) |
| WO (1) | WO2019007356A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020000029A (es) * | 2017-07-05 | 2020-08-06 | Jiangyin Mucocare Pharmaceutical Co Ltd | Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. |
| CN111601618A (zh) * | 2018-09-14 | 2020-08-28 | 江阴贝瑞森制药有限公司 | 孟鲁司特与肽的新缀合物 |
| CN113613657A (zh) * | 2019-01-10 | 2021-11-05 | 江阴优培尔康药业有限公司 | 含有白三烯受体拮抗剂的新型配制品 |
| MX2022003057A (es) * | 2019-09-14 | 2022-06-16 | Jiangyin Usun Pharmaceutical Co Ltd | Nuevos peptidos. |
| CA3160167A1 (en) * | 2019-12-02 | 2021-06-10 | Ming Gu | Peptides and their use in the treatment of inflammation |
| US20230331792A1 (en) * | 2019-12-02 | 2023-10-19 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New multi-functional oligopeptides |
| CA3166799A1 (en) * | 2020-02-03 | 2021-08-12 | Vered Rosenberger | Topical montelukast formulations |
| US12233055B2 (en) | 2020-02-03 | 2025-02-25 | Taro Pharmaceutical Industries Ltd. | Topical Montelukast formulations |
| US20230372324A1 (en) | 2020-10-13 | 2023-11-23 | Diomed Developments Ltd. | Gel formulations comprising montelukast |
| CN114588267A (zh) * | 2020-12-04 | 2022-06-07 | 江苏恒瑞医药股份有限公司 | 一种含酰胺类局部麻醉药的药物组合物 |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| US20240165247A1 (en) * | 2021-03-17 | 2024-05-23 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptide conjugates |
| JP2024530484A (ja) * | 2021-08-06 | 2024-08-21 | エンリティザ（シャンハイ）ファーマシューティカル カンパニー リミテッド | 免疫不全障害の新規治療 |
| CN116421547A (zh) * | 2023-03-09 | 2023-07-14 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2230571T3 (es) * | 1995-12-28 | 2005-05-01 | Mitsubishi Pharma Corporation | `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria. |
| US20030207932A1 (en) | 2002-05-03 | 2003-11-06 | Morris Mann | Compositions that prevent post-traumatic hyperpigmentation and methods related thereto |
| WO2005013885A2 (en) * | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| US6987170B1 (en) * | 2004-08-09 | 2006-01-17 | Battelle Energy Alliance, Llc | Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis |
| WO2007126865A2 (en) * | 2006-03-30 | 2007-11-08 | Patrin Pharma | Leukotriene antagonists via nasal drug delivery |
| CN1961867A (zh) | 2006-11-16 | 2007-05-16 | 徐英权 | 孟鲁司特钠的颗粒剂型 |
| WO2008105803A1 (en) | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and uses thereof |
| WO2008106081A1 (en) * | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation |
| US20110124681A1 (en) | 2008-05-06 | 2011-05-26 | Schlesinger Larry S | Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof |
| CA2653011A1 (en) * | 2008-12-03 | 2010-06-03 | Apotex Technologies Inc | Method and apparatus for packaging and dispensing pharmaceuticals |
| GB0915319D0 (en) | 2009-09-03 | 2009-10-07 | Sharma Anant | Combination medicament |
| CN101773503A (zh) | 2010-01-12 | 2010-07-14 | 北京华禧联合科技发展有限公司 | 一种白三烯拮抗剂和抗组胺药组合物 |
| KR20130050952A (ko) | 2010-06-16 | 2013-05-16 | 브루스 챈들러 메이 | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
| CN102895661A (zh) * | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
| WO2013100564A1 (ko) | 2011-12-26 | 2013-07-04 | 에스케이케미칼 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용 가능한 염을 포함한 구강투여용 필름 |
| CN103239450B (zh) | 2012-02-07 | 2014-11-26 | 齐鲁制药有限公司 | 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法 |
| MX382776B (es) * | 2013-03-13 | 2025-03-13 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. |
| CN103655497B (zh) | 2013-12-18 | 2018-05-29 | 北京华禧联合科技发展有限公司 | 一种孟鲁司特钠口腔崩解片及其制备方法 |
| JP6893075B2 (ja) * | 2014-08-04 | 2021-06-23 | 日東電工株式会社 | 液性免疫誘導促進用組成物及びワクチン医薬組成物 |
| CN105769825A (zh) | 2014-12-24 | 2016-07-20 | 广州朗圣药业有限公司 | 一种孟鲁司特钠的口腔膜剂及其制备方法 |
| CN105878215A (zh) | 2014-12-31 | 2016-08-24 | 天津康鸿医药科技发展有限公司 | 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途 |
| WO2016148455A2 (ko) * | 2015-03-13 | 2016-09-22 | 경희대학교 산학협력단 | 몬테루카스트의 생체이용률을 개선시키기 위한 방법 |
| CN104784157B (zh) | 2015-04-04 | 2018-06-26 | 齐鲁制药有限公司 | 一种稳定的孟鲁司特口腔薄膜剂 |
| WO2017011983A1 (zh) * | 2015-07-20 | 2017-01-26 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白用于皮肤和皮肤附属器官的防护 |
| KR102468519B1 (ko) * | 2015-07-20 | 2022-11-21 | 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 | 피부 염증의 억제에서의 홍합 접착 단백질 제품 및 이의 적용 |
| EP3419676B1 (en) * | 2016-02-22 | 2022-08-31 | Board of Regents, The University of Texas System | Antimicrobial compositions and uses thereof |
| US10548837B1 (en) | 2016-05-04 | 2020-02-04 | Taro Pharmaceutical Industries Ltd. | Topical montelukast for treatment of atopic dermatitis |
| MX2020000029A (es) * | 2017-07-05 | 2020-08-06 | Jiangyin Mucocare Pharmaceutical Co Ltd | Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. |
| JP7742226B2 (ja) * | 2018-05-28 | 2025-09-19 | ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド | 新たな医薬品使用 |
| CN111601618A (zh) * | 2018-09-14 | 2020-08-28 | 江阴贝瑞森制药有限公司 | 孟鲁司特与肽的新缀合物 |
| CN113613657A (zh) * | 2019-01-10 | 2021-11-05 | 江阴优培尔康药业有限公司 | 含有白三烯受体拮抗剂的新型配制品 |
-
2018
- 2018-07-04 MX MX2020000029A patent/MX2020000029A/es unknown
- 2018-07-04 EP EP18827979.8A patent/EP3648767A4/en active Pending
- 2018-07-04 MA MA052924A patent/MA52924A/fr unknown
- 2018-07-04 KR KR1020207003363A patent/KR102785243B1/ko active Active
- 2018-07-04 AU AU2018295944A patent/AU2018295944B2/en active Active
- 2018-07-04 CA CA3068818A patent/CA3068818A1/en active Pending
- 2018-07-04 CN CN202110903665.3A patent/CN113491696A/zh active Pending
- 2018-07-04 CN CN201880002883.6A patent/CN110312513B/zh active Active
- 2018-07-04 WO PCT/CN2018/094441 patent/WO2019007356A1/en not_active Ceased
- 2018-07-04 CN CN202210843681.2A patent/CN115300508A/zh active Pending
- 2018-07-04 MY MYPI2020000043A patent/MY201703A/en unknown
- 2018-07-04 JP JP2019572791A patent/JP7288404B2/ja active Active
- 2018-07-04 US US16/628,170 patent/US11672792B2/en active Active
- 2018-07-04 SG SG11201911841PA patent/SG11201911841PA/en unknown
- 2018-07-05 TW TW107123334A patent/TWI874298B/zh active
-
2023
- 2023-05-01 US US18/310,020 patent/US20230404992A1/en not_active Abandoned
-
2024
- 2024-12-11 US US18/977,212 patent/US20250302818A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200039677A (ko) | 2020-04-16 |
| AU2018295944B2 (en) | 2023-12-14 |
| AU2018295944A1 (en) | 2020-02-20 |
| KR102785243B1 (ko) | 2025-03-26 |
| US20250302818A1 (en) | 2025-10-02 |
| CN113491696A (zh) | 2021-10-12 |
| WO2019007356A1 (en) | 2019-01-10 |
| EP3648767A4 (en) | 2021-04-28 |
| SG11201911841PA (en) | 2020-01-30 |
| JP7288404B2 (ja) | 2023-06-07 |
| US11672792B2 (en) | 2023-06-13 |
| CA3068818A1 (en) | 2019-01-10 |
| TWI874298B (zh) | 2025-03-01 |
| EP3648767A1 (en) | 2020-05-13 |
| JP2020527134A (ja) | 2020-09-03 |
| CN110312513A (zh) | 2019-10-08 |
| MY201703A (en) | 2024-03-13 |
| MX2020000029A (es) | 2020-08-06 |
| CN110312513B (zh) | 2022-07-08 |
| US20210145819A1 (en) | 2021-05-20 |
| CN115300508A (zh) | 2022-11-08 |
| US20230404992A1 (en) | 2023-12-21 |
| TW201919633A (zh) | 2019-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3648767A4 (en) | TOPICAL FORMULATIONS WITH MONTELUKAST AND COMBINATIONS WITH SHELL ADHESION PROTEINS | |
| EP3756079A4 (en) | OBJECT GENERATION WITH PHYSICAL MANIPULATION | |
| EP3713530A4 (en) | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE FOR IT | |
| EP3618871A4 (en) | FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES | |
| MA49043A (fr) | Formulation stable d'anticorps | |
| EP3813431C0 (en) | NETWORK FUNCTION PROCESSING IN THE CONTEXT OF INTER-MANAGEMENT FUNCTION MOBILITY | |
| EP3634976A4 (en) | DETERMINATION OF SMALL MOLECULAR PROTEIN AND PROTEIN-PROTEIN INTERACTIONS | |
| MA48442A (fr) | Structure d'extérieur | |
| EP3871532C0 (en) | HOUSING AND AROMA INSERTER WITH IT | |
| ZA202101250B (en) | Novel crispr-associated protein and use thereof | |
| MA54052A (fr) | Formulation d'anticorps | |
| EP3685828A4 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITION, OPHTHALMIC KIT, AND PHARMACEUTICAL USE THEREOF | |
| EP3415518A4 (en) | MACROCYCLUS AND COMPOSITION THEREOF | |
| EP3399033A4 (en) | PEPTIDE MARKING AND MARKED PROTEIN THEREOF | |
| EP3489295A4 (en) | FIRE-RESISTANT MOLDED BODY AND MOLDED ARTICLES WITH THE FIRE-RESISTANT MOLDED BODY | |
| EP3330155A4 (en) | RAIL VEHICLE AND CONNECTOR THEREFOR | |
| MA54139A (fr) | Formulation d'anticorps | |
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| EP3466452A4 (en) | FRAGRANCE-RELEASING MODULE AND FRAGRANCE-RELEASING CONTAINER THEREFOR | |
| EP3538560A4 (en) | GDNF FUSION POLYPEPTIDES AND METHOD FOR USE THEREOF | |
| EP3780979C0 (en) | MEN'S UNDERWEAR | |
| EP3741376A4 (en) | PROBIOTICS FOR INHIBITING AND PREVENTING THE PROGRESS OF KIDNEY DISEASE AND COMPOSITIONS FOR INHIBITING AND PREVENTING THE PROGRESS OF RENAL DISEASE THEREOF | |
| EP3307239A4 (en) | FORMULATIONS FOR RELEASE OF RSV AND NOROVIRUS ANTIGENES IN THE THINNER | |
| EP3611668C0 (en) | MOISTURE SENSORS | |
| EP3401364A4 (en) | ASPHALT MODIFIER AND ASPHALT COMPOSITION THEREWITH |